Viscosupplementation Industry Analysis in Europe (2025 - 2035)

Viscosupplementation Industry Analysis in Europe Size, Share Forecast and Outlook 2025 to 2035

The Europe viscosupplementation market is projected to expand from USD 523.9 million in 2025 to USD 869.8 million by 2035, registering a steady 5.2% CAGR during the forecast period. This growth is being driven by the rising prevalence of osteoarthritis, demographic aging, and the growing preference for non-surgical joint therapies.

As patients seek alternatives that offer pain relief without long recovery times, viscosupplementation is emerging as a key treatment modality. Advancements in hyaluronic acid-based formulations, including cross-linked HA and bio-fermented variants, are improving clinical outcomes while reducing the frequency of injections.

Multi-injection and single-dose regimens are gaining traction across outpatient settings, particularly in Western Europe, where reimbursement support and awareness campaigns are increasing patient access. Additionally, the expansion of orthopedic centers and sports medicine clinics is contributing to greater adoption.

The competitive landscape is evolving as manufacturers focus on high-molecular-weight formulations, enhanced biocompatibility, and longer residence time in joints. This shift is supported by rising healthcare expenditure on degenerative joint disease management and an uptick in early diagnosis.

Sedentary lifestyles, obesity, and sports-related injuries are fueling demand for minimally invasive interventions even among younger and middle-aged demographics. As a result, viscosupplementation is being repositioned from a last-resort therapy to a first-line treatment option.

Vendors are leveraging biotechnology innovations and targeted delivery systems to meet the growing need for personalized orthobiologic care. The emergence of outcome-based models in joint preservation is also influencing buying behavior across both public and private healthcare networks.

Government regulations play a critical role in shaping the viscosupplementation market in Europe. Under the EU Medical Device Regulation (MDR 2017/745), viscosupplements are subject to stringent clinical, safety, and post-market surveillance requirements. Depending on their formulation, products are classified as Class III medical devices or medicinal products, overseen by the European Medicines Agency (EMA). Country-specific agencies like G-BA in Germany and HAS in France require additional health technology assessments for reimbursement eligibility.

These frameworks aim to promote product innovation while ensuring safety, efficacy, and performance accountability. Collectively, these regulations foster a structured environment that supports long-term market growth and high-quality therapeutic outcomes.

Metric	Value
Industry Size (2025E)	USD 523.9 million
Industry Value (2035F)	USD 869.8 million
CAGR (2025 to 2035)	5.2%

Regulatory and Coverage Status Across Europe Viscosupplementation Market

HA knee injections are treated as medical devices, not pharmaceuticals, which shapes how they are regulated and paid for

• EU‑wide classification: Typically Class III medical devices under MDR (EU) 2017/745, with CE‑marking based on clinical evaluation rather than EMA drug authorisation.
• UK (NICE NG226, 2022): Explicitly recommends against intra‑articular hyaluronan injections for managing osteoarthritis. Corticosteroids may be used for short‑term relief.
• Germany: Considered an IGeL (self‑pay) procedure; IGeL‑Monitor rates the benefit as “tendenziell negativ,” even though it remains one of the most common private services.
• France: De‑reimbursed from December 1, 2017 following HAS/CEPS reviews that judged benefit insufficient; pre‑2017 use was widespread.
• Spain (SESCS HTA): Found insufficient evidence to justify public funding for knee, hip, or other joints; regions like Asturias follow similar cautious policies.

Implications for Reporting and Market Analysis of Europe Viscosupplementation

• Utilisation mirrors reimbursement, not disease prevalence. When coverage is withdrawn or discouraged (France, UK NHS, Germany GKV), injections shift to self‑pay channels, where volumes disappear from official counts.

Guidelines diverge: EULAR (2021) leaves HA use to individual judgment, while OARSI (2019) gives a conditional recommendation only for selected knee‑OA patients. UK NHS materials fully align with NICE, favoring steroids over HA.

Viscosupplementation Market Analyzed by Top Investment Segments

The market is segmented based on product, molecular weight, end user, and region. By product, the market is divided into single injection viscosupplementation, three injection viscosupplementation, five injection viscosupplementation, and next generation (steroid combination).

In terms of molecular weight, it is segmented into high molecular weight, medium molecular weight, and low molecular weight. Based on end user, the market is categorized into hospitals, specialty clinics, and ambulatory surgical centers. Regionally, the market is classified into Western Europe and Eastern Europe.

Next-Generation Formulations to Witness Demand

The next generation (steroid combination) segment is projected to be the fastest-growing in the viscosupplementation market, registering a CAGR of 6.8% between 2025 and 2035. This segment is outperforming the overall market growth rate of 5.2%, primarily due to its ability to combine the lubricating benefits of hyaluronic acid with the anti-inflammatory properties of corticosteroids.

These formulations offer enhanced pain relief, reduced synovial inflammation, and improved joint functionality, making them particularly appealing in early and moderate stages of osteoarthritis. Their convenience as dual-action therapies reduces the frequency of injections, increasing compliance and preference in ambulatory care settings.

The ability to deliver quick symptom relief without surgical intervention has positioned these products favorably among healthcare providers. Increasing clinical trials supporting safety and efficacy, along with strong physician endorsements, are accelerating product uptake across Europe. As patient expectations evolve toward faster, non-invasive outcomes, this segment is poised to gain widespread market traction.

Product	CAGR (2025 to 2035)
Next Generation (Steroid Combination)	6.8%

High Molecular Weight Formulations Witness Adoption Due to High Viscoelasticity

High molecular weight formulations continue to dominate the viscosupplementation market, favored for their prolonged joint lubrication, high viscoelasticity, and strong clinical results in moderate to severe knee osteoarthritis. These formulations reduce the need for frequent injections, improve patient outcomes, and are widely used in both hospital and specialty clinic settings.

However, medium molecular weight formulations are emerging as the fastest-growing category within this segment, projected to grow at a CAGR of 6.2% from 2025 to 2035. Their popularity stems from their balanced efficacy, ease of administration, and relatively lower cost, making them more accessible to broader patient populations, especially in publicly funded healthcare systems.

These formulations are increasingly adopted in Western and Eastern Europe, where demand for mid-range therapies with acceptable durability is rising. As clinical trials support comparable benefits with fewer adverse reactions, medium-weight options are capturing the attention of providers seeking to optimize therapeutic value while maintaining affordability.

Molecular Weight	CAGR (2025 to 2035)
Medium Molecular Weight	6.2%

Ambulatory Surgical Centers Gain Momentum as Cost-Effective Outpatient Hubs

The ambulatory surgical centers (ASCs) segment is the fastest-growing end-user category in the viscosupplementation market, projected to register a CAGR of 7.1% between 2025 and 2035. ASCs have become critical care points for delivering outpatient joint therapies due to their efficiency, cost-effectiveness, and minimal wait times.

Increasing demand for same-day treatments and reduced hospital stays is driving the uptake of viscosupplementation procedures in these settings. With lower overhead costs than hospitals, ASCs offer a more affordable treatment pathway, especially for patients without extensive comorbidities. Their flexibility in scheduling, targeted orthopedic services, and use of streamlined digital health tools make them highly suitable for younger and active patient cohorts.

Additionally, Europe’s shift toward value-based care is reinforcing the expansion of outpatient networks like ASCs. As insurers and health systems encourage decentralized care delivery, viscosupplementation procedures in ASCs are expected to see robust growth across urban and semi-urban centers.

End User	CAGR (2025 to 2035)
Ambulatory Surgical Centers	7.1%

Key Europe Viscosupplementation Market Dynamics

Aging Population and Osteoarthritis Prevalence Drive Procedural UptakeThe market is being driven by the growing incidence of osteoarthritis and the increasing need for minimally invasive treatment options among the aging population across Europe.

With longer life expectancy and more sedentary lifestyles, joint degeneration has become a significant healthcare concern. Viscosupplementation, particularly hyaluronic acid-based injections, is being adopted to reduce joint pain, improve mobility, and delay surgical interventions. Western European nations are expanding access to orthopedic services through public health systems, and outpatient adoption is rising due to convenience and reduced recovery time.

Technological innovations, such as cross-linked HA and steroid-combination formulations, are enhancing clinical effectiveness and broadening use cases across all stages of osteoarthritis. These developments are making viscosupplementation a central part of joint preservation strategies and promoting long-term cost savings in public healthcare delivery.

Reimbursement Variability and Regulatory Burden Constrain Market Expansion

Despite increased demand, inconsistent reimbursement policies and complex regulatory frameworks are limiting market scalability across the region. Countries like Germany and France require strict evaluations by authorities such as G-BA and HAS before granting reimbursement approval, creating delays in product availability.

Additionally, the EU Medical Device Regulation (MDR 2017/745) imposes extensive clinical validation and post-market surveillance requirements, posing compliance challenges, especially for small and mid-sized manufacturers. These barriers can hinder innovation and restrict access in less-developed parts of Eastern Europe, where procedural awareness and orthopedic infrastructure remain limited.

The variability in treatment guidelines across nations adds to this complexity, making it difficult for suppliers to establish uniform go-to-market strategies or optimize pricing models.

Outpatient Care Expansion and Personalized Treatment Models Unlock Growth

Growing investments in ambulatory surgical centers (ASCs) and specialty orthopedic clinics are creating new growth avenues for viscosupplementation products.

These centers offer lower-cost alternatives to hospital-based care and are ideal for elective joint procedures like viscosupplementation. At the same time, healthcare providers are moving toward personalized medicine, leveraging patient-specific data to optimize injection regimens based on disease severity, activity level, and comorbidities. Advancements in biomaterials and formulation engineering are enabling next-generation viscosupplements that offer extended efficacy, fewer injections, and improved tolerability.

This shift is opening the market to younger demographics and active adults seeking to delay joint replacement surgery. Vendors that deliver tailored, value-based solutions are well-positioned to capitalize on this evolving care model.

Price Competition and Safety Concerns Threaten Market Stability

As competition intensifies, the influx of low-cost generic hyaluronic acid injectables is placing downward pressure on pricing, especially in publicly funded healthcare systems. These price dynamics can erode margins for premium products and may incentivize buyers to prioritize affordability over efficacy.

At the same time, concerns over post-injection adverse events, such as local inflammation or allergic reactions, are prompting regulators to heighten product safety standards. Failure to meet these requirements could result in restricted use or market withdrawal. Fragmented supply chains in Eastern Europe further complicate quality control and brand trust.

In an increasingly regulated environment, companies must invest in robust pharmacovigilance and product differentiation to protect and maintain their market share. Without this, negative clinical outcomes or safety issues could undermine physician and patient confidence in viscosupplementation as a reliable therapy.

Analyzing Top Countries in Europe Specializing in Viscosupplementation

Countries	CAGR (2025 to 2035)
United Kingdom	5.4%
France	5.1%
Germany	5.3%
Italy	5%
Spain	5.2%

United Kingdom

The United Kingdom viscosupplementation market is projected to expand at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2035. Growth is being propelled by a rising elderly population and a shift toward non-surgical treatments for osteoarthritis.

Though NHS coverage remains limited, private providers in major cities are rapidly increasing the use of single-injection and cross-linked hyaluronic acid treatments. Import-reliant supply chains are being localized through partnerships with pharmacies and clinical distributors. Research hubs like Oxford and Cambridge are supporting clinical trials, improving product visibility. As orthopedic consultations rise, hospital procurement patterns are also shifting toward newer-generation products.

Awareness campaigns and training for general practitioners are expanding therapeutic exposure. Custom dosage formats and integrated pain relief injections are being explored. Despite reimbursement limitations, accessibility is growing via self-pay and insurance channels. Rising incidence of joint-related disorders and improved therapy outcomes are expected to keep the UK at the forefront of Europe’s viscosupplementation adoption.

France

France’s viscosupplementation market is projected to record a CAGR of 5.1% between 2025 and 2035. An aging population and evolving healthcare policies are supporting wider adoption of intra-articular hyaluronic acid. France benefits from robust regulatory support, with HAS assessments promoting product inclusion in insurance formularies.

Leading hospitals often employ both single-dose and three-dose regimens, particularly in older patients. Local manufacturers play a crucial role, producing cross-linked variants that are widely used across Western Europe. Public healthcare infrastructure ensures access to therapies through hospitals and orthopedic centers. Rising preventive care focus and physiotherapy-led joint pain programs are also encouraging early intervention. Consumer preference for minimally invasive solutions is growing, enhancing outpatient procedure volumes.

Recent product upgrades are offering longer duration relief, prompting physicians to recommend injections more widely. National awareness campaigns and orthopedic congresses are educating clinicians on product variety and safety. These factors collectively establish France as a steady, innovation-ready market for viscosupplementation.

Germany

Germany is expected to grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2035, driven by its robust orthopedic infrastructure and dual reimbursement model. With G-BA regulating public reimbursement and private insurers offering flexible terms, the country enjoys a hybrid access structure.

Viscosupplementation is widely adopted in orthopedic clinics and sports medicine facilities, particularly for the early stages of knee osteoarthritis. Germany hosts multiple OEMs and CMOs contributing to regional manufacturing and export. Medium-to-high molecular weight formulations are gaining popularity due to longer efficacy. Hospitals prefer evidence-based products, leading to a surge in clinically validated brands. Physician confidence is reinforced through national guidelines promoting viscosupplement use.

Digitally enabled patient tracking and follow-up systems are also enhancing therapy adherence. Several companies are piloting gel-based or extended-release variants, which may improve dosing efficiency. With an aging demographic and a well-organized specialist network, Germany continues to drive innovation and reliability in the viscosupplementation landscape.

Italy

Italy’s viscosupplementation market is estimated to progress at a CAGR of 5% from 2025 to 2035. The increasing demand for non-surgical interventions and the high elderly population are key growth drivers. Northern Italy, in particular, exhibits robust activity from orthopedic and physiotherapy clinics that utilize multi-dose and combined steroid therapies. While public reimbursement varies by region, the government is attempting to streamline national policies under its healthcare harmonization initiatives.

Italy still imports most of its viscosupplementation products, but is gradually building local distribution strength through specialty pharmacy chains. Urban centers such as Milan and Turin report higher procedure volumes, driven by insurance-backed access. Education efforts are underway to train general practitioners on appropriate patient selection and administration. Manufacturers are targeting tailored formulations, aiming to reduce injection frequency.

Consumer trust is increasing, especially in post-COVID health awareness environments. With the convergence of policy updates and patient demand, Italy is poised for measured and sustainable market advancement.

Spain

Spain’s viscosupplementation market is predicted to achieve a CAGR of 5.2% from 2025 to 2035. The market is expanding due to increased joint disorders and wider availability of outpatient therapy. In regions like Madrid and Barcelona, private clinics are accelerating the use of cross-linked hyaluronic acid injections.

Public sector growth is more gradual, owing to fragmented reimbursement policies governed by autonomous communities. However, investments in ambulatory surgical centers and physical therapy hubs are addressing access gaps. Spain relies heavily on imports, yet its internal distribution system ensures timely supply to clinics and hospitals. Educational efforts targeting orthopedists and physiotherapists are enhancing therapy awareness.

Demand for single-injection and combination formulations is climbing, especially among older populations seeking fast recovery. Mobile health units and tele-consult platforms are improving patient follow-ups. As Spain aligns its healthcare infrastructure with minimally invasive pain management trends, viscosupplementation is emerging as a standard orthopedic offering.

Europe Viscosupplementation Market Players Strategy Analysis

The competitive landscape of the Europe viscosupplementation market is moderately consolidated, with leading multinational players and specialized regional firms competing through innovation, regulatory expertise, and localized distribution. Major companies such as Sanofi, Zimmer Biomet, and Anika Therapeutics dominate the landscape with well-established brands like Synvisc-One®, Durolane®, and Monovisc®.

These firms leverage strong R&D capabilities, extensive clinical validation, and wide hospital networks to maintain their leadership. European pharmaceutical companies like FidiaFarmaceutici and Ferring Pharmaceuticals are strengthening regional influence with proprietary formulations and dual-action viscosupplements such as Hymovis®. Mid-tier firms including Bioventus and Mylan (now part of Viatris) are actively targeting outpatient segments with cost-effective, single-injection alternatives.

Strategic priorities across the market include expanding reimbursement coverage, developing longer-lasting formulations, and building outpatient-focused distribution models. Key players are also investing in cross-linked hyaluronic acid research, steroid-combination technologies, and post-injection comfort enhancements.

Regulatory compliance under EU MDR 2017/745 and post-market surveillance remain central to competitiveness. Although larger players dominate major Western European markets, niche providers are gaining momentum in Eastern Europe, where lower entry costs and public-private partnerships allow tailored market approaches.

Innovation, real-world clinical outcomes, and country-specific alignment with orthopedic care models are increasingly critical to capturing and retaining share in this evolving therapeutic space.

Sanofi continues to lead the viscosupplementation market through Synvisc® and Synvisc-One®, widely used in France, Germany, and the UK. The company emphasizes robust clinical data, broad practitioner education programs, and consistent manufacturing quality.

Zimmer Biomet is focused on expanding its European reach through Durolane® and Gel-One®, targeting improved joint lubrication with fewer injections. In 2023, it introduced enhanced cross-linked HA formulations aimed at younger osteoarthritis patients seeking outpatient care.

Anika Therapeutics is expanding through strategic partnerships in Western Europe, promoting Orthovisc® and Monovisc® as medium-to-high molecular weight solutions. The company is focused on penetrating specialty clinics and ambulatory surgical centers with single-injection options.

FidiaFarmaceutici, a key regional player, is advancing Hymovis® across Southern and Eastern Europe through localized partnerships and new delivery formats that appeal to cost-conscious healthcare systems.

Bioventus and Ferring Pharmaceuticals are targeting the value segment with economically viable viscosupplementation options. Their strategies include physician training programs, country-specific pricing models, and integration with physical rehabilitation services. As the market evolves, companies combining innovation with regional adaptability and regulatory compliance are best positioned to capture long-term growth.

Recent Europe Viscosupplementation Industry News

• In April 2025, Zimmer Biomet Holdings, Inc., a global medical technology leader, announced it has completed the acquisition of Paragon 28, a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space.
• In December 2024, Gevo, Inc. and LG Chem, leading global chemical companies committed to producing sustainable products, announced that they are extending their joint development agreement. The agreement extension enables LG Chem to assess existing assets for deploying Gevo’s Ethanol-to-Olefins (“ETO”) technology while accelerating commercialization activities, considering project scale and end-product markets.
• In June 2024, Helsinn Group and Chugai Pharma Europe signed a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland.

Report Scope Table for the Europe Viscosupplementation Market

Attribute	Details
Current Total Market Size (2025)	USD 523.9 million
Projected Market Size (2035)	USD 869.8 million
CAGR (2025 to 2035)	5.2%
Base Year for Estimation	2024
Historical Period	2020 to 2024
Projections Period	2025 to 2035
Report Parameter	Revenue in USD million/volume in units
By Product	Single Injection Viscosupplementation, Three Injection Viscosupplementation, Five Injection Viscosupplementation, and Next Generation (Steroid Combination)
By Molecular Weight	High Molecular Weight, Medium Molecular Weight, and Low Molecular Weight
By End User	Hospitals, Specialty Clinics, and Ambulatory Surgical Centers
Regions Covered	Western Europe and Eastern Europe
Countries Covered	United Kingdom, France, Germany, Italy, Spain
Key Players	Zimmer Biomet, Meda Pharma (Mylan), OrthogenRx, LG Chem, Hanmi Pharm. Co., Ltd., Chugai Pharmaceutical Co. Ltd., Haohai Biological Technology, Meiji Seika Pharma Co. Ltd., Chroma Pharma, Sanofi, Anika Therapeutics, Bioventus, Fidia Farmaceutici, Seikagaku Corporation
Additional Attributes	Dollar sales by value, market share analysis by region, and country-wise analysis

Key Segment Covered

By Product:

Single Injection Viscosupplementation, Three Injection Viscosupplementation, Five Injection Viscosupplementation, Next Generation (Steroid Combination)

By Molecular Weight:

High Molecular Weight, Medium Molecular Weight, Low Molecular Weight

By End User:

Hospitals, Ambulatory Surgical Centers and Specialty Clinics